Literature DB >> 25471174

Elderly multiple myeloma patients experience less deterioration in health-related quality of life than younger patients compared to a normative population: a study from the population-based PROFILES registry.

M W M van der Poel1, S Oerlemans, H C Schouten, L V van de Poll-Franse.   

Abstract

The objectives of this study were to compare health-related quality of life (HRQOL) between multiple myeloma (MM) patients aged ≤65 and >65 years and to compare this with a normative population. Factors associated with HRQOL were identified. The population-based Eindhoven Cancer Registry was used to select MM patients diagnosed from 1999 to 2010. Patients (n = 289) were invited to complete the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) and Quality of Life Questionnaire Multiple Myeloma Module 20 (QLQ-MY20), and 212 patients responded (73 %). Data from the normative population (n = 568) were used for comparison. MM patients >65 years scored better on emotional functioning (p < 0.05) and financial problems (p < 0.01) compared to patients ≤65 years. Patients ≤65 years reported better body image and future perspective (p < 0.01). Compared to the normative population, patients ≤65 years scored worse on all EORTC QLQ-C30 functioning scales and on global health/QOL, fatigue, pain, dyspnea, appetite loss, and financial problems (p < 0.01). Patients >65 years scored worse on social, physical, and role functioning and on global health/QOL, fatigue, pain, and dyspnea (p < 0.01). Younger patients had worse HRQOL compared to the normative population than elderly patients. Patients with comorbidities reported lower QOL. The longer the time since diagnosis, the better the physical functioning. No major differences in HRQOL were found between younger and older MM patients. Compared to that of the normative population, HRQOL in younger patients was worse than that in older patients. The number of comorbidities and time since diagnosis were associated with HRQOL. MM patients reported that a high symptom burden and therapy should, besides prolonging survival, be aimed at improving HRQOL.

Entities:  

Mesh:

Year:  2014        PMID: 25471174     DOI: 10.1007/s00277-014-2264-0

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  16 in total

1.  Geriatric assessment and quality of life changes in older adults with newly diagnosed multiple myeloma undergoing treatment.

Authors:  Hira Mian; Gregory R Pond; Sascha A Tuchman; Mark A Fiala; Tanya M Wildes
Journal:  J Geriatr Oncol       Date:  2020-05-27       Impact factor: 3.599

2.  Quality of life in cancer patients with or without medication-related osteonecrosis of the jaw.

Authors:  Sara de Cassia Tornier; Fernanda Joly Macedo; Laurindo Moacir Sassi; Juliana Lucena Schussel
Journal:  Support Care Cancer       Date:  2021-05-10       Impact factor: 3.603

3.  Assessing health-related quality of life in cancer survivors: factors impacting on EORTC QLU-C10D-derived utility values.

Authors:  Thomas van Gelder; Brendan Mulhern; Dounya Schoormans; Olga Husson; Richard De Abreu Lourenço
Journal:  Qual Life Res       Date:  2020-01-14       Impact factor: 4.147

4.  Symptom clusters and quality of life in ambulatory patients with multiple myeloma.

Authors:  Fengjiao Chen; Yamei Leng; Jingyao Ni; Ting Niu; Li Zhang; Jiping Li; Yuhuan Zheng
Journal:  Support Care Cancer       Date:  2022-02-19       Impact factor: 3.603

5.  Impact of Comorbidities on Health-related Quality of Life in Nontransplant Eligible Patients With Newly Diagnosed Multiple Myeloma.

Authors:  M Christine Bennink; Claudia A M Stege; Birgit I Lissenberg-Witte; Simone Oerlemans; Maarten R Seefat; Pieter Sonneveld; Sonja Zweegman
Journal:  Hemasphere       Date:  2022-06-21

Review 6.  Myeloma in Elderly Patients: When Less Is More and More Is More.

Authors:  Ashley Rosko; Sergio Giralt; Maria-Victoria Mateos; Angela Dispenzieri
Journal:  Am Soc Clin Oncol Educ Book       Date:  2017

7.  Chemotherapy-induced neuropathy in multiple myeloma: influence on quality of life and development of a questionnaire to compose common toxicity criteria grading for use in daily clinical practice.

Authors:  A J M Beijers; G Vreugdenhil; S Oerlemans; M Eurelings; M C Minnema; C M Eeltink; L V van de Poll-Franse; F Mols
Journal:  Support Care Cancer       Date:  2015-12-03       Impact factor: 3.603

8.  Symptom burden and its functional impact in patients with "symptomatic" relapsed or refractory multiple myeloma.

Authors:  Mona Kamal; Xin Shelley Wang; Qiuling Shi; Teresa M Zyczynski; Catherine Davis; Loretta A Williams; Hui-Kai Lin; Araceli Garcia-Gonzalez; Charles S Cleeland; Robert Orlowski
Journal:  Support Care Cancer       Date:  2020-05-11       Impact factor: 3.603

9.  The influence of baseline characteristics and disease stage on health-related quality of life in multiple myeloma: findings from six randomized controlled trials.

Authors:  Don Robinson; Dixie-Lee Esseltine; Antoine Regnault; Juliette Meunier; Kevin Liu; Helgi van de Velde
Journal:  Br J Haematol       Date:  2016-06-05       Impact factor: 6.998

10.  Defining a set of standardised outcome measures for newly diagnosed patients with multiple myeloma using the Delphi consensus method: the IMPORTA project.

Authors:  Joan Blade; Miguel Ángel Calleja; Juan José Lahuerta; José Luis Poveda; Héctor David de Paz; Luis Lizán
Journal:  BMJ Open       Date:  2018-02-22       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.